Metformin exposure and the incidence of lactic acidosis in critically ill patients with T2DM: A retrospective cohort study.

IF 2.6 4区 综合性期刊 Q2 MULTIDISCIPLINARY SCIENCES Science Progress Pub Date : 2024-07-01 DOI:10.1177/00368504241262116
Jingkai Tong, Xin Li, Tong Liu, Ming Liu
{"title":"Metformin exposure and the incidence of lactic acidosis in critically ill patients with T2DM: A retrospective cohort study.","authors":"Jingkai Tong, Xin Li, Tong Liu, Ming Liu","doi":"10.1177/00368504241262116","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to investigate the correlation between metformin exposure and the incidence of lactic acidosis in critically ill patients.</p><p><strong>Methods: </strong>The patients with type 2 diabetes mellitus (T2DM) were included from Medical Information Mart for Intensive Care IV database (MIMIC-IV). The primary outcome was the incidence of lactic acidosis. The secondary outcomes were lactate level and in-hospital mortality. Propensity score matching (PSM) method was adopted to reduce bias of the confounders. The multivariate logistic regression was used to explore the correlation between metformin exposure and the incidence of lactic acidosis. Subgroup analysis and sensitivity analysis were used to test the stability of the conclusion.</p><p><strong>Results: </strong>We included 4939 patients. There were 2070 patients in the metformin group, and 2869 patients in the nonmetformin group. The frequency of lactic acidosis was 5.7% (118/2070) in the metformin group and it was 4.3% (122/2869) in the nonmetformin group. There was a statistically significant difference between the two groups (<i>P < </i>0.05). The lactate level in the metformin group was higher than in the nonmetformin group (2.78 ± 2.23 vs. 2.45 ± 2.24, <i>P < </i>0.001). After PSM, the frequency of lactic acidosis (6.3% vs. 3.7%, <i>P </i>< 0.001) and lactate level (2.85 ± 2.38 vs. 2.40 ± 2.14, <i>P < </i>0.001) were significantly higher in the metformin group compared with the nonmetformin group. In multivariate logistic models, the frequency of lactic acidosis was obviously increased in metformin group, and the adjusted odds ratio (<i>OR</i>) of metformin exposure was 1.852 (<i>95% confidence interval (CI) = </i>1.298-2.643, <i>P </i>< 0.001). The results were consistent with subgroup analysis except for respiratory failure subgroup. Metformin exposure increased lactate level but did not affect the frequency of lactic acidosis in patients of respiratory failure with hypercapnia. However, the in-hospital mortality between metformin and nonmetformin group had no obvious difference (<i>P </i>= 0.215). In sensitivity analysis, metformin exposure showed similar effect as the original cohort.</p><p><strong>Conclusions: </strong>In critically ill patients with T2DM, metformin exposure elevated the incidence of lactic acidosis except for patients of respiratory failure with hypercapnia, but did not affect the in-hospital mortality.</p>","PeriodicalId":56061,"journal":{"name":"Science Progress","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11282515/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Progress","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1177/00368504241262116","RegionNum":4,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The objective of this study was to investigate the correlation between metformin exposure and the incidence of lactic acidosis in critically ill patients.

Methods: The patients with type 2 diabetes mellitus (T2DM) were included from Medical Information Mart for Intensive Care IV database (MIMIC-IV). The primary outcome was the incidence of lactic acidosis. The secondary outcomes were lactate level and in-hospital mortality. Propensity score matching (PSM) method was adopted to reduce bias of the confounders. The multivariate logistic regression was used to explore the correlation between metformin exposure and the incidence of lactic acidosis. Subgroup analysis and sensitivity analysis were used to test the stability of the conclusion.

Results: We included 4939 patients. There were 2070 patients in the metformin group, and 2869 patients in the nonmetformin group. The frequency of lactic acidosis was 5.7% (118/2070) in the metformin group and it was 4.3% (122/2869) in the nonmetformin group. There was a statistically significant difference between the two groups (P < 0.05). The lactate level in the metformin group was higher than in the nonmetformin group (2.78 ± 2.23 vs. 2.45 ± 2.24, P < 0.001). After PSM, the frequency of lactic acidosis (6.3% vs. 3.7%, P < 0.001) and lactate level (2.85 ± 2.38 vs. 2.40 ± 2.14, P < 0.001) were significantly higher in the metformin group compared with the nonmetformin group. In multivariate logistic models, the frequency of lactic acidosis was obviously increased in metformin group, and the adjusted odds ratio (OR) of metformin exposure was 1.852 (95% confidence interval (CI) = 1.298-2.643, P < 0.001). The results were consistent with subgroup analysis except for respiratory failure subgroup. Metformin exposure increased lactate level but did not affect the frequency of lactic acidosis in patients of respiratory failure with hypercapnia. However, the in-hospital mortality between metformin and nonmetformin group had no obvious difference (P = 0.215). In sensitivity analysis, metformin exposure showed similar effect as the original cohort.

Conclusions: In critically ill patients with T2DM, metformin exposure elevated the incidence of lactic acidosis except for patients of respiratory failure with hypercapnia, but did not affect the in-hospital mortality.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
二甲双胍暴露与 T2DM 重症患者乳酸酸中毒的发生率:一项回顾性队列研究。
研究目的本研究旨在探讨二甲双胍暴露与重症患者乳酸酸中毒发生率之间的相关性:方法:2型糖尿病(T2DM)患者被纳入重症监护医学信息市场IV数据库(MIMIC-IV)。主要结果是乳酸酸中毒的发生率。次要结果为乳酸水平和院内死亡率。采用倾向得分匹配法(PSM)减少混杂因素的偏差。采用多变量逻辑回归探讨二甲双胍暴露与乳酸酸中毒发生率之间的相关性。采用亚组分析和敏感性分析检验结论的稳定性:我们共纳入了 4939 例患者。结果:我们纳入了 4939 例患者,其中二甲双胍组 2070 例,非二甲双胍组 2869 例。二甲双胍组乳酸酸中毒发生率为 5.7%(118/2070),非二甲双胍组为 4.3%(122/2869)。两组之间的差异有统计学意义(P 0.05)。二甲双胍组的乳酸水平高于非二甲双胍组(2.78 ± 2.23 vs. 2.45 ± 2.24,P 0.001)。PSM 后,二甲双胍组发生乳酸酸中毒的频率(6.3% vs. 3.7%,P 0.001)明显高于非二甲双胍组。在多变量逻辑模型中,二甲双胍组发生乳酸酸中毒的频率明显增加,二甲双胍暴露的调整赔率(OR)为 1.852(95% 置信区间(CI)= 1.298-2.643,P P = 0.215)。在敏感性分析中,二甲双胍暴露显示出与原始队列相似的效果:结论:在患有 T2DM 的重症患者中,二甲双胍会增加乳酸酸中毒的发生率,但呼吸衰竭合并高碳酸血症的患者除外,但不会影响院内死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Science Progress
Science Progress Multidisciplinary-Multidisciplinary
CiteScore
3.80
自引率
0.00%
发文量
119
期刊介绍: Science Progress has for over 100 years been a highly regarded review publication in science, technology and medicine. Its objective is to excite the readers'' interest in areas with which they may not be fully familiar but which could facilitate their interest, or even activity, in a cognate field.
期刊最新文献
Comparison of the effect of combination therapies in the treatment of large varicose ulcers: A real-world cohort study Hydraulic loss experiment of straight-through Tesla valve in forward and reverse directions A review of neonatal lupus syndrome A review of research on tire burst and vehicle stability control Early and late blight disease identification in tomato plants using a neural network-based model to augmenting agricultural productivity
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1